Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally
Go back to Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 230.25 +4.33 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $225.92 | 52 Week High | $160.00 | |||
| Open | $225.27 | 52 Week Low | $95.80 | |||
| Day High | $230.94 | P/E | 42.80 | |||
| Day Low | $222.93 | EPS | $5.38 | |||
| Volume | 862,820 | |||||
